ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 6 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 9 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - peginterferon alfa 2a 135 mcg / 0.5 ml - solution for injection - peginterferon alfa-2a - chronic hepatitis b: pegasys is indicated for the treatment of both hbeag- positive and hbeag -negative chronic hepatitis b in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.chronic hepatitis c: pegasys is indicated for the treatment of chronic hepatitis c in adult patients who are positive for serum hcv-rna including patients with compensated cirrhosis and/or co-infected with clinically stable hiv. the optimal way to use pegasys in patients with chronic hepatitis c is in combination with ribavirin. the combination of pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - peginterferon alfa 2a 180 mcg / 0.5 ml - solution for injection - peginterferon alfa-2a - chronic hepatitis b: pegasys is indicated for the treatment of both hbeag- positive and hbeag -negative chronic hepatitis b in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.chronic hepatitis c: pegasys is indicated for the treatment of chronic hepatitis c in adult patients who are positive for serum hcv-rna including patients with compensated cirrhosis and/or co-infected with clinically stable hiv. the optimal way to use pegasys in patients with chronic hepatitis c is in combination with ribavirin. the combination of pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - tocilizumab - תרכיז להכנת תמיסה לאינפוזיה - tocilizumab 20 mg/ml - tocilizumab - tocilizumab - actemra (tocilizumab) is indicated for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response to one or more dmards (disease modifying antirhematic drugs) or tnf antagonists or in whom dmards cannot be used. actemra can be used alone or in combination with methotrexate or other dmards.actemra® has been shown to reduce progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. actemra® is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - mefloquine as hydrochloride 250 mg - tablets - mefloquine - for the treatment and prophylaxis of plasmodium falciparum malaria which is resistant to other antimalarials.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - recombinant human deoxyribonuclease - תמיסה לשאיפה - recombinant human deoxyribonuclease 1 mg/ml - dornase alfa (desoxyribonuclease) - dornase alfa (desoxyribonuclease) - management of cystic fibrosis not for patients under 5 years of age or with fvc<40% .

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - flumazenil 0.1 mg/ml - solution for injection - flumazenil - benzodiazepine antagonist for reversal of benzodiazepine anasthesia, as well as for patients with benzodiazepine intoxication.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - ocrelizumab - תרכיז להכנת תמיסה לאינפוזיה - ocrelizumab 30 mg/ml - ocrelizumab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - alectinib as hydrochloride - קפסולות - alectinib as hydrochloride 150 mg